Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
Imbruvica, Calquence and Venclexta demonstrate good results in combination regimens.
In a recent study, Dana-Farber scientists and others uncovered a key part of why some patients eventually become resistant to Venclexta.
Calquence is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.
Quincy’s treatment would take him and his family to the frontier of using precision medicine to find a drug to save the infant’s life.
September was designated as National Blood Cancer Awareness Month in 2010 by United States Congress.
Recent legislation may help narrow the gap between FDA approval of cancer medications for adults and children.
The combination of chemoimmunotherapy with a targeted drug represents a step toward a new standard of care for people with CLL.
Trying to mimic the “Berlin Patient” cure, researchers edited the CCR5 gene in the immune stem cells of a man with leukemia and HIV.
“Radiation can cause cancer and non-cancer outcomes, but it does not cause every type of cancer and non-cancer outcome.”
Some of the most common and deadly cancers receive little attention and resources.
Targeted therapy combination reduced the risk of disease progression or death by 65% in a randomized study.
Phil Catudal credits his early cancer experience with his motivational approach to wellness.
Using mouse models, the study focused on why asparaginase—a natural enzyme used as a drug to treat the blood cancer—doesn’t always work.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.